3 recruiting, 1 withdrawn. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Progression: new trials by email Literature Review of Progression trials Research Report on Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors Everolimus 5 MG - Neuroendocrine Tumors, Progression | Phase 2 | Recruiting | AC Camargo Cancer Center | 100 | 2024-04-24 | 2024-06-25 |
| Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma Stereotactic Body Radiation Therapy - Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Recruiting | Yale University | 30 | 2023-12-22 | 2025-12-04 |
| A Prospective, Two-center, Single Arm Phase II Clinical Study to Evaluate Safety and Effectiveness of Ablation Therapy in the Treatment of Lung Cancer Presenting as Ground-glass Nodules Ablation therapy - Progression | Phase 2 | Recruiting | Shanghai Zhongshan Hospital | 120 | 2021-01-01 | 2021-05-27 |
| Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma Famitinib, Ifosfamide, Camrelizumab - Effect of Drugs, Progression | Phase 1 / Phase 2 | Withdrawn | Peking University People's Hospital | 2019-08-15 | 2020-05-19 |
Disease Progression (4) · Adenoma, Islet Cell (1) · Carcinoid Tumor (1) · Carcinoma, Renal Cell (1) · Neoplasms (1) · Neuroendocrine Tumors (1)
Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Adenocarcinoma (2) · Carcinoma (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Adenoma (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1)
Everolimus (1) · Ifosfamide (1) · Radiosurgery (1) · camrelizumab (1) · famitinib (1)
AC Camargo Cancer Center (1) · Peking University People's Hospital (1) · Shanghai Zhongshan Hospital (1) · Yale University (1)
China (2) · Brazil (1) · United States (1)
Kimberly Johung, MD (1) · Wei Guo, Ph.D. and M.D. (1)